- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
- Interventions
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
- Interventions
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas